🇺🇸 FDA

Company profile · Sponsor

Vir

Vir Biotechnology

VIR · NYSE biotech SAN FRANCISCO, CA, USA
Pipeline
24
Drugs
0
Patents
6

Quick answer

Vir (VIR) is a biotech company. headquartered in SAN FRANCISCO, CA, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 6 patents to this profile..

Company facts

Ticker VIR
Exchange NYSE
Company type biotech
Headquarters SAN FRANCISCO, CA, USA
SEC CIK 0001706431

Pipeline (24)

Search pipeline →

  1. LY3819253

    Vir

    Covid19

    phase 3 mab completed

    1 trial

  2. Tobevibart

    Vir

    Viral Hepatitis

    phase 3 small molecule active

    3 trials

  3. VIR-2218, VIR-3434, HEPCLUDEX 2 mg powder for solution for injection

    Vir

    Chronic Hepatitis D Virus (HDV) Infection

    phase 3 small molecule active

    1 trial

  4. VIR-3434, VIR-2218

    Vir

    Chronic Hepatitis D Virus (HDV) Infection

    phase 3 small molecule active

    1 trial

  5. VIR-7831

    Vir

    COVID-19

    phase 3 mab completed

    1 trial

  6. VIR-7831 (sotrovimab)

    Vir

    Covid19

    phase 3 mab completed

    1 trial

  7. sotrovimab

    Vir

    Covid19

    phase 3 mab terminated

    3 trials

  8. BRII-179

    Vir

    For Treatment of Chronic Hepatitis B Virus Infection

    phase 2 mab active

    1 trial

  9. BRII-835 (VIR-2218)

    Vir

    Hepatitis B, Chronic

    phase 2 small molecule completed

    1 trial

  10. Bamlanivimab

    Vir

    COVID-19

    phase 2 small molecule completed

    1 trial

  11. HEPCLUDEX 2 mg powder for solution for injection, VIR-2218, VIR-3434

    Vir

    Chronic Hepatitis D Virus (HDV) Infection

    phase 2 small molecule active

    1 trial

  12. PEG-IFNα

    Vir

    Chronic Hepatitis B Virus Infection

    phase 2 mab active

    1 trial

  13. Pegasys 180 micrograms solution for injection in pre-filled syringe, VIR-3434, Viread 245 mg film-coated tablets, VIR-2218

    Vir

    Chronic Hepatitis B Virus (HBV) Infection

    phase 2 small molecule active

    1 trial

  14. Sotrovimab

    Vir

    COVID-19

    phase 2 mab terminated

    1 trial

  15. Sotrovimab (Gen1)

    Vir

    Covid19

    phase 2 mab completed

    1 trial

  16. Tenofovir Alafenamide

    Vir

    Chronic Hepatitis B

    phase 2 small molecule completed

    1 trial

  17. VIR-2218

    Vir

    Hepatitis B, Chronic

    phase 2 small molecule completed

    1 trial

  18. VIR-2218

    Vir

    Hepatitis D, Chronic

    phase 2 small molecule active

    1 trial

  19. VIR-2482 (450 mg)

    Vir

    Influenza A

    phase 2 mab terminated

    1 trial

  20. VIR-3434

    Vir

    Hepatitis B, Chronic

    phase 2 small molecule completed

    1 trial

  21. VIR-3434, VIR-2218

    Vir

    Chronic Hepatitis D Virus (HDV) Infection

    phase 2 small molecule active

    1 trial

  22. VIR-5818

    Vir

    Locally Advanced or Metastatic HER2-Expressing Cancers

    phase 2 small molecule active

    1 trial

  23. Vir-3434, Vir-2218, Pegasys 180 micrograms solution for injection in pre-filled syringe

    Vir

    Chronic Hepatitis B Virus Infection

    phase 2 small molecule active

    1 trial

  24. A Phase 1 First-in-Human Study of the Safety and Effects of VIR-5818 Alone or with Pembrolizumab in Participants with Advanced or Metastatic HER2-Expressing Cancers

    Vir

    Participants with Locally Advanced or Metastatic HER2-Expressing Cancers

    phase 1 other active

    1 trial

Patents (6)

Search patents →

  1. US 12404318

    Combination HBV therapy

    Expires Mon Aug 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11628215

    HIV vaccines comprising one or more population episensus antigens

    Expires Mon Apr 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11554168

    HIV vaccines comprising one or more population episensus antigens

    Expires Mon Jan 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11479599

    Antibodies against SARS-CoV-2 and methods of using the same

    Expires Mon Oct 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11168128

    Antibodies against SARS-CoV-2 and methods of using the same

    Expires Mon Nov 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10894078

    HIV vaccines comprising one or more population episensus antigens

    Expires Mon Jan 14 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Vir?

Vir (VIR) is a biotech company. headquartered in SAN FRANCISCO, CA, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 6 patents to this profile..

What pipeline programs does Vir sponsor?

We track 24 ClinicalTrials.gov-linked programs for Vir, including LY3819253 and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Vir company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.